Johnson & Johnson is reportedly in talks to acquire a partner that’s developing a linchpin of its future immunology plans. J&J and Protagonist Therapeutics are in discussions for a buyout, the Wall Street Journal reported Friday, citing people familiar with the matter. The exact parameters of the deal were not disclosed, and it’s not certain that a deal will take place. Protagonist’s stock $PTGX surged Friday morning by more than 35%, rising above $90 per share for the first time in the company’s history. As of Thursday’s market close, Protagonist had a market cap of $4.06 billion.
Read the full article: J&J Is in Discussions to Buy Out Protagonist Therapeutics – Report //
Source: https://endpoints.news/jj-is-in-discussions-to-buy-out-protagonist-therapeutics-report/